On April 23, 2025, Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic platform against a range of cancer indications, emerged from stealth with $20 million in seed financing. Playground Global and Godfrey Capital were among the investors in the funding round.

Wilson Sonsini Goodrich & Rosati advised Synthetic Design Lab on the transaction. The team that advised Synthetic Design Lab included Ken Clark, Lance Brady, and Alison Sechrest.

For more information, please see Synthetic Design Lab’s press release. Additional coverage can be found on San Francisco Business Times and Endpoints.